Project Grant R43CA298267
Award Date
7/9/25
Completion Date
6/30/26
Dollars Obligated
$399K
Federal Agency
National Cancer Institute
Awardee
Alelopharma Inc. (WAKKU35UEN73)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $1,280,908 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Exai Bio Inc., a small disadvantaged business in Palo Alto, California. The grant supports the development of a novel assay and artificial intelligence (AI) model for early detection of non-small cell lung cancer (NSCLC) and predicting its subtypes using orphan non-coding RNA (oncRNA) biomarkers. The goal is to create a liquid biopsy-based diagnostic...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...
This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $399,998 Project Grant to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The goal of this 1-year Phase I project is to adapt Darwin Biosciences' existing platform, which was developed under a separate DoD contract, to detect circulating tumor DNA biomarkers for non-small cell lung cancer using saliva and...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $1,999,108.00 to Orbit Genomics, Inc. to develop a high-sensitivity, high-specificity lung cancer subtyping diagnostic test. The goal is to create a test that can accurately distinguish between different lung cancer subtypes, which is critical for selecting the most effective treatment and reducing mortality. This new subtyping capability will be added to Orbit...
The National Cancer Institute (NCI) awarded a $990,771 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Binary Genomics, Inc., a minority-owned for-profit organization located in Madison, CT. The project aims to build clinical data supporting the use of Binary Genomics' circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of lung cancer immunotherapies. The technology leverages epigenetic features to broadly detect ctDNA without...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $670,147 to Vanderbilt University Medical Center to conduct research aimed at improving the clinical sensitivity of circulating tumor DNA (ctDNA) liquid biopsies. The research program has three key objectives: 1) Elucidating the role of the RNA binding protein SAM68 in mediating cell-free DNA (cfDNA) release, 2) Pharmacologically optimizing cfDNA release and stability to...
This Project Grant award of $399,444.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cancure LLC, a woman-owned small business, aims to screen a panel of fusion proteins composed of a peptide and a binding agent. The goal is to identify the best candidate to advance or make a go/no-go decision regarding the fusion product, while also conducting pilot de-risking biochemical/biophysical characterizations. This research seeks to develop a novel agent...
This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $305,000.00 in funding to Innotech Precision Medicine, Inc. to develop a microfluidic device for multi-omics diagnosis of cancer. The project aims to create a portable, saliva-based diagnostic system that can rapidly detect cancer biomarkers for early diagnosis, particularly for head and neck cancers. The research will focus on integrating multiple...
This $649,486 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cedars-Sinai Medical Center aims to develop an innovative, minimally invasive liquid biopsy assay that can identify molecular subtypes of lethal prostate cancer. The key objectives are to: Perform analytical validation of technologies for isolating large oncosomes (LO) from patient plasma samples for clinical use. Develop a multianalyte LO-based assay to detect lethal...